Massive 23,000-Patient study tests new stroke drug in hospitals nationwide
NCT ID NCT06707987
Summary
This large study observed how a clot-dissolving drug called non-immunogenic staphylokinase worked for patients having a stroke in real hospital settings. It involved over 23,000 adults who received the drug within 4.5 hours of their stroke symptoms starting. The main goal was to see how safe the treatment was and how well patients recovered, measuring their ability to function independently 90 days later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Federal Brain and Neurotechnology Center
Moscow, 117513, Russia
Conditions
Explore the condition pages connected to this study.